Jihad Georges Youssef1,2, Philip Lavin3, David A Schoenfeld4, Richard A Lee5, Rainer Lenhardt6, David J Park7, Javier Perez Fernandez8, Melvin L Morganroth9, Jonathan C Javitt10,11, Dushyantha Jayaweera12. 1. Houston Methodist Pulmonary Transplant Center, Houston Methodist Hospital, Houston, TX. 2. Department of Academic Pulmonology, Houston Methodist Hospital, Houston, TX. 3. Boston Biostatistics Research Foundation Inc, Framingham, MA. 4. Massachusetts General Hospital, Harvard Medical School, Boston, MA. 5. University of California, Irvine, CA. 6. The University of Louisville, Louisville, KY. 7. St. Jude Medical Center, Fullerton, CA. 8. Baptist Hospital, Miami, FL. 9. Oregon Clinic, Portland, OR. 10. Johns Hopkins University School of Medicine, Baltimore, MD. 11. NRx Pharmaceuticals, Inc., Wilmington, DE. 12. The University of Miami, Miller School of Medicine, Miami, FL.
Abstract
OBJECTIVES: Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive intestinal peptide (VIP) is shown in nonclinical studies to upregulate surfactant production, inhibit cytokine synthesis, prevent cytopathy, and block replication of the severe acute respiratory syndrome coronavirus 2 virus in pulmonary cells. The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 respiratory failure compared with placebo and demonstrate biological effects in such patients. DESIGN: A multicenter, placebo-controlled trial. SETTING: Ten U.S. hospitals: six tertiary-care hospitals and four community hospitals. PATIENTS: A total of 196 patients with COVID-19 respiratory failure. INTERVENTIONS: Participants were randomized 2:1 to receive 3 days of IV Aviptadil or placebo. MEASUREMENTS AND MAIN RESULTS: The primary end point (alive and free from respiratory failure at day 60) did not reach statistical significance (odds ratio [OR], 1.6; 95% CI, 0.86-3.11) for patients treated with Aviptadil when controlling for baseline ventilation status as prespecified in the protocol. There was, however, a statistically significant two-fold odds of improved survival (OR, 2.0; 95% CI, 1.1-3.9) at 60 days ( p = 0.035). There was significant improvement in respiratory distress ratio and reduced interleukin 6 cytokine release ( p = 0.02) by day 3.Subgroup analysis identified a statistically significant likelihood of achieving primary end point among those treated with high-flow nasal oxygen at baseline ( p = 0.039). Subjects on mechanical ventilation also experienced a 10-fold increased odds of survival with drug versus placebo ( p = 0.031). CONCLUSIONS: The primary end point did not reach statistical significance, indicating that there was no difference between Aviptadil versus placebo. However, Aviptadil improves the likelihood of survival from respiratory failure at day 60 in critical COVID-19 across all sites of care. Given the absence of drug-related serious adverse events and acceptable safety profile, we believe the benefit versus risk for the use of Aviptadil is favorable for patient treatment.
OBJECTIVES: Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive intestinal peptide (VIP) is shown in nonclinical studies to upregulate surfactant production, inhibit cytokine synthesis, prevent cytopathy, and block replication of the severe acute respiratory syndrome coronavirus 2 virus in pulmonary cells. The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 respiratory failure compared with placebo and demonstrate biological effects in such patients. DESIGN: A multicenter, placebo-controlled trial. SETTING: Ten U.S. hospitals: six tertiary-care hospitals and four community hospitals. PATIENTS: A total of 196 patients with COVID-19 respiratory failure. INTERVENTIONS: Participants were randomized 2:1 to receive 3 days of IV Aviptadil or placebo. MEASUREMENTS AND MAIN RESULTS: The primary end point (alive and free from respiratory failure at day 60) did not reach statistical significance (odds ratio [OR], 1.6; 95% CI, 0.86-3.11) for patients treated with Aviptadil when controlling for baseline ventilation status as prespecified in the protocol. There was, however, a statistically significant two-fold odds of improved survival (OR, 2.0; 95% CI, 1.1-3.9) at 60 days ( p = 0.035). There was significant improvement in respiratory distress ratio and reduced interleukin 6 cytokine release ( p = 0.02) by day 3.Subgroup analysis identified a statistically significant likelihood of achieving primary end point among those treated with high-flow nasal oxygen at baseline ( p = 0.039). Subjects on mechanical ventilation also experienced a 10-fold increased odds of survival with drug versus placebo ( p = 0.031). CONCLUSIONS: The primary end point did not reach statistical significance, indicating that there was no difference between Aviptadil versus placebo. However, Aviptadil improves the likelihood of survival from respiratory failure at day 60 in critical COVID-19 across all sites of care. Given the absence of drug-related serious adverse events and acceptable safety profile, we believe the benefit versus risk for the use of Aviptadil is favorable for patient treatment.
Authors: Björn C Frye; Frank Meiss; Dagmar von Bubnoff; Gernot Zissel; Joachim Müller-Quernheim Journal: N Engl J Med Date: 2020-06-25 Impact factor: 91.245
Authors: Ventzislav Petkov; Wilhelm Mosgoeller; Rolf Ziesche; Markus Raderer; Leopold Stiebellehner; Karin Vonbank; Georg-Christian Funk; Gerhard Hamilton; Clemens Novotny; Bernhard Burian; Lutz-Henning Block Journal: J Clin Invest Date: 2003-05 Impact factor: 14.808
Authors: Dawn M Bravata; Anthony J Perkins; Laura J Myers; Greg Arling; Ying Zhang; Alan J Zillich; Lindsey Reese; Andrew Dysangco; Rajiv Agarwal; Jennifer Myers; Charles Austin; Ali Sexson; Samuel J Leonard; Sharmistha Dev; Salomeh Keyhani Journal: JAMA Netw Open Date: 2021-01-04
Authors: Merrick Zwarenstein; Shaun Treweek; Joel J Gagnier; Douglas G Altman; Sean Tunis; Brian Haynes; Andrew D Oxman; David Moher Journal: BMJ Date: 2008-11-11
Authors: Maria Boesing; Kristin Abig; Michael Brändle; Martin Brutsche; Emanuel Burri; Björn C Frye; Stéphanie Giezendanner; Jan C Grutters; Philippe Haas; Justian Heisler; Fabienne Jaun; Anne B Leuppi-Taegtmeyer; Giorgia Lüthi-Corridori; Joachim Müller-Quernheim; Reto Nüesch; Wolfgang Pohl; Frank Rassouli; Jörg D Leuppi Journal: Trials Date: 2022-09-20 Impact factor: 2.728